# Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer

> **NCT06671262** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 74 (estimated)

## Conditions studied

- Breast Adenocarcinoma

## Interventions

- **RADIATION:** SBRT
- **DRUG:** Immuno-chemotherapy

## Key facts

- **NCT ID:** NCT06671262
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-26
- **Primary completion:** 2026-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06671262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06671262, "Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06671262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*